Focus: Tessera Therapeutics is a gene-writing biotech focused on in vivo gene editing for rare diseases, based in Somerville, MA. The company operates at pre-revenue stage with early-stage clinical programs.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net +2 jobs in 30d
3 added, 1 removed. Backfill posture.
5 recent layoff filings (12 mo) — 168 affected
Source: state DOL filings via Big Local News
A high-risk, high-upside early-stage play best suited to risk-tolerant candidates who value platform exposure and rare-disease focus over stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tessera Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tessera Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Layoff Tracker: Neumora, enGene cut staff in cost-saving initiatives - BioSpace
Layoff Tracker: Neumora, enGene cut staff in cost-saving initiatives BioSpace
Tessera says infusion edits 85% of blood cells, pointing to off-the-shelf sickle cell fix - Endpoints News
Tessera says infusion edits 85% of blood cells, pointing to off-the-shelf sickle cell fix Endpoints News
Regeneron and Tessera partner to develop gene therapy for AATD - European Pharmaceutical Review
Regeneron and Tessera partner to develop gene therapy for AATD European Pharmaceutical Review
Biotech layoffs pick back up as 14 companies cut 745 jobs in Q1 - The Business Journals
Biotech layoffs pick back up as 14 companies cut 745 jobs in Q1 The Business Journals
Grant supports Tessera’s genetic approaches to HIV cure - BioWorld News
Grant supports Tessera’s genetic approaches to HIV cure BioWorld News
Tessera’s TSRA-196 designated orphan drug for AATD - BioWorld News
Tessera’s TSRA-196 designated orphan drug for AATD BioWorld News
Showing 6 of 8 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Major organizational restructuring in Q1 2026 reflects severe financial or strategic crisis; stability is severely compromised.